Amicus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch FOLD and buy or sell other stocks, ETFs, and their options commission-free!

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company, which engages in discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. 

CEO
Bradley Lewis Campbell
CEOBradley Lewis Campbell
Employees
511
Employees511
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2002
Founded2002
Employees
511
Employees511

FOLD Key Statistics

Market cap
4.55B
Market cap4.55B
Price-Earnings ratio
-163.54
Price-Earnings ratio-163.54
Dividend yield
Dividend yield
Average volume
2.89M
Average volume2.89M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$14.50
52 Week high$14.50
52 Week low
$5.51
52 Week low$5.51

Stock Snapshot

Amicus Therapeutics(FOLD) stock is priced at $14.49, giving the company a market capitalization of 4.55B. It carries a P/E multiple of -163.54.

Amicus Therapeutics(FOLD) stock opened on 2026-04-28 at —. The price climbed to — and dipped to —.

The Amicus Therapeutics(FOLD)'s current trading volume is 0, compared to an average daily volume of 2.89M.

In the last year, Amicus Therapeutics(FOLD) shares hit a 52-week high of $14.50 and a 52-week low of $5.51.

In the last year, Amicus Therapeutics(FOLD) shares hit a 52-week high of $14.50 and a 52-week low of $5.51.

FOLD News

Simply Wall St 4d
Assessing Amicus Therapeutics Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects

Advertisement Why Amicus Therapeutics is on investors’ radar today Amicus Therapeutics (FOLD) has caught investor attention after recent performance data show...

Assessing Amicus Therapeutics Valuation After Recent Share Price Momentum And Rare Disease Growth Prospects
TipRanks 5d
Amicus Gains Final Approval for BioMarin Acquisition Completion

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own FOLD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.